DCM
NBIX icon

Defilade Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Defilade Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-209,932
Closed -$27.7M – 48
2026
Q1 		$27.7M Buy
+209,932
New +$27.9M 3.88% 11

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Defilade Capital Management's NBIX Position: Q2 2026 in Review

Defilade Capital Management sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 209,932 shares — an estimated $27.7M sold.

Defilade Capital Management first reported a position in NBIX in Q1 2026 and held it in 1 quarter. The position peaked at $27.7M in Q1 2026. 774 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Defilade Capital Management reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Defilade Capital Management sold 209,932 Neurocrine Biosciences shares in Q2 2026, an estimated $27.7M.
  • Defilade Capital Management first reported a position in Neurocrine Biosciences in Q1 2026 and held it in 1 quarter.
  • Defilade Capital Management's Neurocrine Biosciences position peaked at $27.7M in Q1 2026.
  • 774 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.